×
About 2,118 results

ALLMedicine™ Paracentesis Center

Research & Reviews  642 results

Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03189108

Jun 24th, 2022 - Background: -Malignant ascites or pleural effusions are often seen in patients with solid tumor malignancies. -Malignant ascites is proinflammatory with many cytokines present and acts to promote tumor cell growth. -The cellular composition of mal...

Body Composition Changes After TIPS and Associated Clinical Outcomes
https://clinicaltrials.gov/ct2/show/NCT05420753

Jun 15th, 2022 - Sarcopenia (loss of muscle mass) and frailty (loss of muscle function) have increasingly become recognized as major prognostic factors in predicting morbidity and mortality with several disease states, including cirrhosis. Cirrhosis represents end...

Final Safety and Efficacy Results from a 106 Real-World Patients Registry with an Ascit...
https://doi.org/10.1111/liv.15337
Liver International : Official Journal of the Internation... Stirnimann G, Berg T et. al.

Jun 11th, 2022 - Patients with cirrhotic refractory ascites ineligible for transjugular intrahepatic shunt (TIPSS) have limited treatment options apart from repeated large volume paracentesis. The alfapump® is an implantable device mobilizing ascites from the peri...

Medical-economic Evaluation of the Care of Refractory Ascites by Implantation of Alfapump® Device in Cirrhotic Patients
https://clinicaltrials.gov/ct2/show/NCT03506893

Jun 10th, 2022 - Refractory ascites is one of the complications associated with portal hypertension in the cirrhotic patient. To date, its treatment consists of evacuating punctures, performed in day hospitalisation, whose frequency is adapted to the rate of ascit...

see more →

Guidelines  2 results

Guidelines on the management of ascites in cirrhosis.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788190
Gut Aithal GP, Palaniyappan N et. al.

Oct 18th, 2020 - The British Society of Gastroenterology in collaboration with British Association for the Study of the Liver has prepared this document. The aim of this guideline is to review and summarise the evidence that guides clinical diagnosis and managemen...

The diagnosis and management of ovarian hyperstimulation syndrome.
https://doi.org/10.1016/S1701-2163(16)35085-X
Journal of Obstetrics and Gynaecology Canada : JOGC = Jou... Shmorgun D, Claman P et. al.

Nov 16th, 2011 - To review the clinical aspects of ovarian hyperstimulation syndrome and provide recommendations on its diagnosis and clinical management. These guidelines will assist in the early recognition and management of ovarian hyperstimulation. Early recog...

see more →

Drugs  9 results see all →

Clinicaltrials.gov  130 results

Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03189108

Jun 24th, 2022 - Background: -Malignant ascites or pleural effusions are often seen in patients with solid tumor malignancies. -Malignant ascites is proinflammatory with many cytokines present and acts to promote tumor cell growth. -The cellular composition of mal...

Body Composition Changes After TIPS and Associated Clinical Outcomes
https://clinicaltrials.gov/ct2/show/NCT05420753

Jun 15th, 2022 - Sarcopenia (loss of muscle mass) and frailty (loss of muscle function) have increasingly become recognized as major prognostic factors in predicting morbidity and mortality with several disease states, including cirrhosis. Cirrhosis represents end...

Medical-economic Evaluation of the Care of Refractory Ascites by Implantation of Alfapump® Device in Cirrhotic Patients
https://clinicaltrials.gov/ct2/show/NCT03506893

Jun 10th, 2022 - Refractory ascites is one of the complications associated with portal hypertension in the cirrhotic patient. To date, its treatment consists of evacuating punctures, performed in day hospitalisation, whose frequency is adapted to the rate of ascit...

Midodrine Versus Albumin for Prevention of Paracentesis Induced Circulatory Disturbance
https://clinicaltrials.gov/ct2/show/NCT05240391

May 10th, 2022 - Paracentesis-induced circulatory disturbance (PICD) is a very common cause of mortality and morbidity in patients undergoing large-volume paracentesis. Albumin is commonly used in decompensated cirrhosis during large-volume paracentesis. However, ...

Developing a Test for the Detection of Ovarian Cancer
https://clinicaltrials.gov/ct2/show/NCT04794322

May 3rd, 2022 - The study aims to elucidate the relative contributions to detection of ovarian cancer from tumor DNA in uterine lavage (UL) and protein biomarkers from blood using newly available detection and sample collection technologies. In this document, the...

see more →

News  64 results

An Academic Hospitalist–Run Outpatient Paracentesis Clinic
https://www.mdedge.com/fedprac/article/252436/hospital-medicine/academic-hospitalist-run-outpatient-paracentesis-clinic
Lawrence D. Gerber, MD, Gaetan Sgro, MD et. al.

Mar 4th, 2022 - Cirrhosis is the most common cause of ascites in the United States. In patients with compensated cirrhosis, the 10-year probability of developing ascites is 47%.

Home-Based System Relieves Refractory Ascites in Cirrhosis
https://www.medscape.com/viewarticle/964970

Dec 16th, 2021 - A home-based tunneled peritoneal catheter (PeCa) drainage system provided significant relief for patients with refractory ascites who were not candidates for transjugular intrahepatic portosystemic shunt (TIPS). For these patients, the current sta...

Home-based system relieves refractory ascites in cirrhosis
https://www.mdedge.com/internalmedicine/article/249961/hepatology/home-based-system-relieves-refractory-ascites-cirrhosis
Jim Kling

Dec 15th, 2021 - A home-based tunneled peritoneal catheter (PeCa) drainage system provided significant relief for patients with refractory ascites who were not candidates for transjugular intrahepatic portosystemic shunt (TIPS). For these patients, the current sta.

Dr. Herzog on the Optimal Use of Bevacizumab in Patients With Ovarian Cancer
https://www.onclive.com/view/dr-herzog-on-the-optimal-use-of-bevacizumab-in-patients-with-ovarian-cancer

Oct 6th, 2021 - Thomas Herzog, MD, professor of obstetrics and gynecology, deputy director, University of Cincinnati Cancer Institute, discusses the optimal use of bevacizumab (Avastin) in patients with ovarian cancer. In June 2018, the FDA approved bevacizumab ...

CDC Reports Burkholderia cepacia and B pseudomallei Outbreaks
https://www.medscape.com/viewarticle/956548

Aug 12th, 2021 - The CDC and FDA have announced an outbreak of at least 15 Burkholderia cepacia infections associated with contaminated ultrasound gel used to guide invasive procedures as well as an unrelated outbreak of Burkholderia pseudomallei that caused two d...

see more →